Uniunea Europeană - română - EMA (European Medicines Agency)

accord healthcare s.l.u. - sunitinib - gastrointestinal stromal tumors; carcinoma, renal cell; neuroendocrine tumors - agenți antineoplazici - gastrointestinal stromal tumour (gist)sunitinib accord is indicated for the treatment of unresectable and/or metastatic malignant gastrointestinal stromal tumour (gist) in adults after failure of imatinib treatment due to resistance or intolerance. metastatic renal cell carcinoma (mrcc)sunitinib accord is indicated for the treatment of advanced/metastatic renal cell carcinoma (mrcc) in adults. pancreatic neuroendocrine tumours (pnet)sunitinib accord is indicated for the treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumours (pnet) with disease progression in adults.

Uniunea Europeană - română - EMA (European Medicines Agency)

sun pharmaceutical industries europe b.v. - sitagliptin fumarate - diabetul zaharat, tip 2 - medicamente utilizate în diabet - for adult patients with type 2 diabetes mellitus, sitagliptin sun is indicated to improve glycaemic control:as monotherapy:- in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance. as dual oral therapy in combination with:- metformin when diet and exercise plus metformin alone do not provide adequate glycaemic control. - a sulphonylurea when diet and exercise plus maximal tolerated dose of a sulphonylurea alone do not provide adequate glycaemic control and when metformin is inappropriate due to contraindications or intolerance. - a peroxisome proliferator-activated receptor gamma (pparγ) agonist (i. a thiazolidinedione) when use of a pparγ agonist is appropriate and when diet and exercise plus the pparγ agonist alone do not provide adequate glycaemic control. as triple oral therapy in combination with:- a sulphonylurea and metformin when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. - a pparγ agonist and metformin when use of a pparγ agonist is appropriate and when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. sitagliptin sun is also indicated as add-on to insulin (with or without metformin) when diet and exercise plus stable dose of insulin do not provide adequate glycaemic control.

Uniunea Europeană - română - EMA (European Medicines Agency)

sun pharmaceutical industries europe b.v. - sitagliptin fumarate, metformin hydrochloride - diabetul zaharat, tip 2 - medicamente utilizate în diabet - for adult patients with type 2 diabetes mellitus:sitagliptin/metformin hydrochloride sun is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. sitagliptin/metformin hydrochloride sun is indicated in combination with a sulphonylurea (i. , terapie triplă) ca adjuvant la dietă și exercițiu fizic, la pacienți controlați inadecvat cu doza maximă tolerată de metformin și o sulfoniluree. sitagliptin/metformin hydrochloride sun is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparγ) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparγ agonist. sitagliptin/metformin hydrochloride sun is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.

România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

sun pharmaceutical industries europe b.v. - olanda - letrozolum - pulb. pt. sol. inj. - 40mg - med. pt. trat. ulcerului gastro-duodenal si bolii-reflux g.e inhibitori ai pompei de protoni

România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

sun pharmaceutical industries europe b.v. - olanda - pemetrexedum - pulb. pt. conc. pt. sol. perf. - 100mg - antimetaboliti analogi ai acidului folic

România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

sun pharmaceutical industries europe b.v. - olanda - pemetrexedum - pulb. pt. conc. pt. sol. perf. - 500mg - antimetaboliti analogi ai acidului folic

România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

sun pharmaceutical industries europe b.v. - olanda - pemetrexedum - pulb. pt. conc. pt. sol. perf. - 1000mg - antimetaboliti analogi ai acidului folic

România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

sun pharmaceutical industries europe b.v. - olanda - esomeprazolum - pulb. pt. sol. inj./perf.  - 40mg - med. pt. trat. ulcerului gastro-duodenal si bolii-reflux g.e inhibitori ai pompei de protoni

România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

sun pharmaceutical industries europe b.v. - olanda - gemcitabinum - pulb. pt. sol. perf. - 200mg - antimetaboliti analogi ai bazelor pirimidinice

România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

sun pharmaceutical industries europe b.v. - olanda - gemcitabinum - pulb. pt. sol. perf. - 1g - antimetaboliti analogi ai bazelor pirimidinice